News

Thursday, 04. April 2013

Antisense Pharma participates in Regensburg „NACHT.SCHAFFT.WISSEN.“

On April 26th, in the context of „NACHT.SCHAFFT.WISSEN.“ Antisense Pharma informs about the development of innovative therapies for targeted treatment of aggressive tumor diseases. For further information more

Tuesday, 26. February 2013

Antisense Pharma unveils revised corporate strategy

New direction for trabedersen´s clinical development program and adjustment of organization to meet its current business objectives.  mehr

Monday, 08. October 2012

Antisense Pharma to present at the upcoming SNO in Washington DC, USA

Professor Peter Hau presents clinical data on trabedersen on Nov. 16th at the 17th Annual Society of NeuroOncology meeting.  mehr

Tuesday, 11. September 2012

Antisense Pharma to present at the upcoming Second International Meeting of the SCIDOT in Chicago, USA

Dr. Hubert Heinrichs presents clinical data on trabedersen during the session “Antisense Pharma Studies” on Oct. 6th.  mehr

Tuesday, 24. July 2012

Antisense Pharma receives FDA Orphan Drug Designation for Trabedersen to treat Malignant Melanoma

Investigational oncology antisense compound trabedersen has gained market exclusivity in the USA for a third aggressive cancer indication, malignant melanoma.  mehr

Monday, 04. June 2012

Today: Antisense Pharma presents completed Phase I/II data at ASCO in Chicago, USA

Trabedersen demonstrated excellent safety combined with encouraging survival in patients with advanced pancreatic cancer and malignant melanoma  mehr

Thursday, 10. May 2012

Antisense Pharma Internationalizes Management Board

Antisense Pharma announces the appointment of Dr. Philippe Calais as CEO. The native-born Frenchman has more than two decades of international experience in executive positions in biotech and pharmaceutical companies  mehr

Monday, 16. April 2012

Antisense Pharma presents at DIA/FDA meeting in Washington, DC

Dr. Hubert Heinrichs presents clinical data on trabedersen during the session "Trabedersen is highly effective against TGF-β2 and shows high efficacy and tolerability in several cancer indications" on April 16th.  mehr

Thursday, 01. March 2012

Antisense Pharma with new Chief Executive Officer (CEO)

Dr. Philippe Calais, international expert for drug commercialization, was appointed as CEO. Dr. Hubert Heinrichs (CMO) held the position as Acting-CEO since July last year. more

Saturday, 04. February 2012

German Science Day: Germany Leads Europe in the Fight Against Cancer

Leading German biotechnology companies working on cancer presented their major research and development results. Antisense Pharmas session introducing the promissing approach with trabedersen can be looked up here more